In vitro decreases of the fibrinolytic potential of cultured human fibrosarcoma cell line, HT1080, by Nigella sativa oil

Phytomedicine

Volumn 12, Issue 1-2, 2005, Pages 100-107

  Awad, E M ^a,b  

^a University of Minia ^*  (Egypt)

^b Otto Meyerhof Zentrum   (Germany)

Author keywords

Fibrinolytic system; HT1080 cells; Nigella sativa; PAI 1; t PA; u PA

Indexed keywords

NIGELLA SATIVA EXTRACT; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLACK CUMIN; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SCREENING; FIBRINOLYSIS; FIBROSARCOMA; HUMAN; HUMAN CELL; METASTASIS INHIBITION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYSIS; FIBROSARCOMA; HUMANS; NIGELLA SATIVA; PHYTOTHERAPY; PLANT OILS; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; URINARY PLASMINOGEN ACTIVATOR;

NIGELLA SATIVA;

EID: 12944298801     PISSN: 09447113     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phymed.2003.09.003     Document Type: Article

References (64)

1. K. Addo-Boadu, J. Wojta, G. Christ, P. Hufnagl, H. Pehamberger, and B.R. Binder Azelaic acid decreases the fibrinolytic potential of cultured human melanoma cells in vitro Cancer Lett. 103 1996 125 129
2. A. Atta-ur Rahman, S. Malik, H. Cunheng, and J. Clardy Isolation and structure determination of nigellicine, a novel alkaloid from the seeds of Nigella sativa Tetrahedron Lett. 26 1985 2759 2762
3. O.A. Badary Thymoquinone attenuates ifosfamide-induced Fanconi syndrome in rats and enhances its antitumor activity in mice J. Ethnopharmacol. 67 2 1999 135 142
4. D.A. Badary, and A.M. Gamal El-Din Inhibitory effects of thymoquinone against 20-methylcholanthrene-induced fibrosarcoma tumorigenesis Cancer Detect Prev. 25 4 2001 362 368
5. O.A. Badary, O.A. Al-Shabanah, M.N. Nagi, A.C. Al-Rikabi, and M.M. Elmazar Inhibition of benzo(a)pyrene-induced forestomach carcinogenesis in mice by thymoquinone Eur. J. Cancer Prev. 8 5 1999 435 440
6. B.R. Binder Influence of urokinase on cell proliferation and invasion Blood Coag. Fibrinol. 1 1990 717 720
7. J. Bizik, R.W. Stephens, and M. Grófóvá Binding of tissue-type plasminogen activator to human melanoma cells J. Cell Biochem. 51 1993 326 335
8. F. Bulens, H. Moreau, A. De Vriese, L. Nelles, and D. Collen Hormonal regulation of the expression of fibrinolytic components in HT1080 fibrosarcoma and endothelial cells Fibrinol. Proteol. 11 1 1997 57 63
9. R.N. Chopra, S.L. Nayar, and I.C. Chopra Glossary of Indian Medicinal Plants 1956 CSIR New Delhi, India p. 175
10. J.K. Christman, S.C. Silverstein, and G. Acs Immunological analysis of plasminogen activators from normal and transformed hamster cells J. Exp. Med. 142 1975 419 434
11. D. Collen, and H. Lijnen Basic and clinical aspects of fibrinolysis and thrombolysis Blood 78 1991 3114 3124
12. M. Colucci, J.A. Paramo, and D. Collen Generation in plasma of a fast acting inhibitor of plasminogen activator in response to endotoxin stimulation J. Clin. Invest. 75 1985 818 824
13. K. Dano, P.A. Andreasen, J. Grondahl-Hansen, P. Kristensen, L.S. Nielsen, and L. Skriver Plasminogen activator tissue degradation, and cancer Adv. Cancer Res. 44 1985 139 266
14. T.J. De Vries, G.N.P. van Muijen, and D.J. Ruiter The plasminogen activation system in tumour invasion and metastasis F. Bosman Pathology Update 1996 Fischer Berlin 1996
15. T.J. De Vries, G.N.P. van Muijen, and D.J. Ruiter The plasminogen activation system in melanoma cell lines and in melanocytic lesions Melanoma Res. 6 1996 79 88
16. I. Galhaup Azelatic acid mode of action at the cellular and subcellular level Acta Dermo-Ventereol. 143 Suppl. 1989 75 82
17. H. Gündüz, S. Dede, Z.T. Agaoglu, N. Atasoy, and N. Mert Serum trace elements status of rabbits supplemented with Nigella sativa, vitamins C and E, and selenium against damage by N-methyl-N′-nitro-nitrosoguanidine Biol. Trace Element Res. 89 2002 65 73
18. N. Hailat, Z. Bataneh, S. Lafi, E. Raweily, M. Aqil, M. Al-Katib, and S. Hanash Effect of Nigella sativa volatile oil on Jurkat T cell leukemia polypeptides Int. J. Pharmacog. 33 1995 16 20
19. K. Huber, J. Kirchheimer, and B.R. Binder Urokinase-type plasminogen activator in some gastrointestinal diseases-application of a specific radioimmunoassay for urokinase antigen J. Jespersen C. Kluft O. Korsguard Clinical Aspects of Fibrinolysis and Thrombolysis 1983 South Jutland University Press Esbjerg 71 82
20. Hur, S.K., Kim, S., Jung, S., Oh, O., Kim, S.S., Lee, S.K., 2001. Inhibition of inducible nitric oxide synthesase activity mediated by resveratrol analogs. Proceedings of the American Association Cancer Research, 22nd Annual Meeting, vol. 42, Abstract No. 98.
21. M. Jang, L. Cai, G.O. Udeani, K.V. Slowing, C.F. Thomas, C.W.W. Beecher, H.H.S. Fong, N.R. Fransworth, A.D. Kinghorn, R.G. Mehta, R.C. Moon, and J.M. Pezzuto Cancer chemopreventive activity of resveratrol, a natural product derived from grapes Science 275 1997 218 220
22. Joe, A.K., Liu, J., Vural, M.E., Xiao, D., Beer, D.G., Ting, W., Weinstein, B., 2001. Resveratrol inhibits growth, induces arrest at the S/G2 transition and apoptosis in several human cancer cell lines. Proceedings of the American Association Cancer Research, 22nd Annual Meeting, vol. 42, Abstract No. 102.
23. M.A.U. Khan, M.K. Ashfaq, H.S. Zuberi, M.S. Mahmoud, and A.H. Gilani The in vivo antifungal activity of the aqueous extract from Nigella sativa seeds Phytother. Res. 17 2003 183 186
24. J.C. Kirchheimer, H. Pflüger, G. Hienert, and B.R. Binder Increased uro-kinase activity to antigen ratio in human renal cell carcinoma Int. J. Cancer 35 1985 737 741
25. J.C. Kirchheimer, K. Huber, P. Polterauer, and B.R. Binder Urokinase antigen in plasma of patients with liver cirrhosis and hepatoma Thromb. Haemos. 54 1985 617 618
26. J.C. Kirchheimer, K. Huber, O. Wagner, and B.R. Binder Pattern of fibrinolytic parameters in patients with gastrointestinal carcinomas Br. J. Haematol. 66 1987 85 89
27. J.C. Kirchheimer, H. Kölbel, G. Tatra, and B.R. Binder Relationship between plasma levels of components of the fibrinolytic system and acute-phase reactants in patients with uterine malignancies Eur. J. Clin. Invest. 20 1990 79 84
28. C. Kluft, J.H. Verheijen, A.F.H. Jie, D.C. Rijken, F.E. Preston, H.M. SueLing, J. Jespersen, and A.O. Aasen The postoperative fibrinolytic shutdown a rapidly reverting acute phase pattern for the fast acting inhibator of tissue-type plasminogen activator after trauma Scand. J. Clin. Lab. Invest. 45 1985 605 610
29. C. Kunz, S. Pebler, J. Otte, and D. von der Ahe Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53 Nucl. Acid Res. 23 1995 3710 3717
30. H.C. Kwaan The plasminogen-plasmin system in malignancy Cancer Metastasis Rev. 11 1992 291 311
31. H. Leibl, G. Stingl, H. Pehamberger, H. Korscan, K. Konrad, and K. Wolff Inhalation of DNA synthesis of melanoma cells by azelatic acid J. Invest. Dermatol. 85 1985 417 422
32. L.R. Lund, J. Rømer, and E. Rønne Urokinase-receptor biosynthesis, mRNA level and gene transcription are induced by transfoming growth factor β1 in human A549 lung carcinomina cells EMBO J. 10 1991 3399 3407
33. D.J. Luskutoff Regulation of PAI-1 gene expresion Fibrinolysis 5 1991 197 206
34. G.M. Mabrouk, S.S. Moselhy, S.F. Zohny, E.M.M. Ali, T.E.A. Helal, A.A. Amin, and A.A. Khalifa Inhibiton of methylnitrosourea (MNU) induced oxidative stress and carcinogenesis by orally administered bee honey and Nigella grains in Sprague-Dawley rats J. Exp. Clin. Cancer Res. 21 3 2002 341 346
35. G. Markus, S.M. Camiolo, S. Kohga, J.M. Madeja, and A. Mittelman Plasminogen activator secretion of human tumors in short-term organ culture; comparison of primary and metastatic colon tumors Cancer Res. 43 1983 5517 5525
36. E. Matsuda, H. Tsuchiya, S. Katsuo, H. Abe, P. Hufnagl, X. Zheng, and B.R. Binder Clonal variation of secretion of plasminogen activators and their inhibitor (PAI-1) and the metastatic potential in human fibrosarcoma (HT-1080) clones Thromb. Haemostas. 69 1993 29
37. A. Meissauer, M.D. Kramer, and M. Hofmann Urokinase-type and tissue-type Plasminogen activators are essential for in vitro invasion of melanoma cells Exp. Cell Res. 192 1991 453 459
38. A. Meissauer, M.D. Kramer, and V. Schirrmacher Generation of cell surface-bound plasmin by cell associated urokinase-type or secreted tissue-type plasminogen activator a key event in melanoma cell invasiveness in vitro Exp. Cell Res. 199 1992 179 190
39. K.M. Nadakarni Corcus sativus, Nigella sativa K.M. Nadkarni Indian Materia Medica 1976 Popular Prakashan Bombay, India 386 411
40. S.C. Nair, M.J. Salomi, B. Panikkar, and K.R. Panikkar Modultory effects of Crocus sativus and Nigella sativa extracts on cisplatin-induced toxicity in mice J. Ethnopharmacol. 31 1991 75 83
41. M. Nazzaro-Porro, S. Passi, L. Balus, and A.S. Breathnach Identification of tyrosinase inhibitors in cultures of pitysporum and their melanotoxic effect Pigment Cell 4 1979 234 243
42. J. Paramo, M. Colucci, D. Collen, and F. van de Werf Plasminogen activator inhibator in the blood of patients with coronary artery disease Br. Med. J. 291 1985 573 574
43. S. Passi, M. Picardo, M. Nazzaro-Porro, A.S. Breathnach, A.M. Confaloni, and G. Seilubi-Crescenzi Antimitochondral effect of saturated medium chain length (C8-C13) dicarboxylic acid Biochem. Pharmacol. 33 1984 103 108
44. J. Pöllänen, O. Saksela, and E.-M. Salonen Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells J. Cell Biol. 104 1987 1085 1086
45. N. Pourreau-Schneider, P. Delori, B. Boutiére, D. Arnoux, F. George, J. Sampol, and P.M. Martin Modulation of plasminogen activator system by matrix components in two breast cancer cell lines MCF-7 and MDA-MB-231 J. Natl. Cancer Inst. 81 1989 259 266
46. Z. Qian, M.E. Gilbert, and M.A. Colicos Tissue plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation Nature 361 1993 453 457
47. P.H.A. Quax, G.N.P. Van Muijen, and E.J.D. Weening-Verhoeff Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor and urokinase mediated matrix degradation J. Cell Biol. 115 1991 191 199
48. I. Resh, G. Krutisch, M. Geiger, and B.R. Binder ELISA systems for active and total plasminogen activator inhibitor 1 (PAI-1) antigen Thromb. Haemost. 62 1989 299
49. A. Riccio, P.V. Pedone, and L.R. Lund Transforming growth factor β1-responsive element closely associated binding sites for USF and CCAT-binding transcription factor-nuclear factor I in the type 1 plasminogen activator inhibitor gene Mol. Cell Biol. 12 1992 1846 1855
50. E.J. Robins, A.S. Breathnach, B.J. Ward, Y.P. Bashin, L. Ethridge, M. Nazzaro-Porro, S. Passi, and M. Picardo Effect of dicarboxylic acids on Harding-Passey and Cloudman S91 melanoma cells in tissue culture J. Invest. Dermatol. 85 1985 216 221
51. N.J. Salomi, S.C. Nair, and K.R. Panikkar Inhibitory effects of Nigella sativa and Saffron (Crocus sativus) on chemical carcinogenesis in mice Nutr. Cancer 16 1991 67 72
52. N.J. Salomi, S.C. Nair, K.K. Jayawardhanan, C.D. Vargghese, and K.R. Pantikkar Anti-tumor principles from Nigella sativa seeds Cancer Lett. 63 1992 41 46
53. R.A. Sharma, C.R. Ireson, R.D. Verschoyle, K.A. Hill, M.L. Williams, C. Leuratti, M.M. Manson, L.J. Marnett, W.P. Steward, and A. Gescher Effects of dietary curcumin on glutathione S-transferase and malondialdehyde-DNA adducts in rat liver and colon mucosa relationship with drug levels Clin. Cancer Res. 7 5 2001 1452 1458
54. M.H. Stack, R.D. Gray, and S.V. Pizzo Modulation of B16F10 melanoma plasminogen activator production by a synthetic peptide from the laminin A chain Cancer Res. 53 1993 1998 2004
55. S.M. Swamy, and B.K. Tan Cytotoxic and immunopotentiating effects of ethanolic extract of Nigella sativa L. seeds J. Ethnopharmacol. 70 1 2000 1 7
56. H. Tsuchiya, S. Katsuo, H. Tsuchiya, C. Sunayama, K. Tomita, Y. Ueda, and B.R. Binder The antibody to plasminogen activator inhibitor-1 suppresses pulmonary metastases of human fibrosarcoma in athymic mice Gen. Diagn. Pathol. 141 1995 41 48
57. J.C. Unkeless, A. Tobias, L. Ossowski, J.P. Quigley, D.B. Rifkin, and E. Reich An enzymatic function associated with transformation of fibroblasts by oncogenic viruses. I. Chick embryo fibroblast cultures transformed by avian RNA tumor viruses J. Exp. Med. 137 1973 85 111
58. O.F. Wagner, and B.R. Binder Purification of an active plasminogen activator inhibitor immunologically related to the endothelial type plasminogen activator inhibitor from the conditioned media of a human melanoma cell line J. Biol. Chem. 261 1986 14474 14481
59. O.F. Wagner, J. Wojta, H. Pehamberger, H. Leibl, and B.R. Binder Effect of dicarboxylic acids on plasminogenic activator activity in supernatants of a human tumor cell line Prog. Fibrinolysis 7 1985 280 282
60. O.F. Wagner, M. Vetterlein, and B.R. Binder Purification of an active plasminogenic activator inhibitor immunologically related to the endothelial type plasminogeni activitor inhibitor from the conditioned media of a human melanoma cell line J. Biol. Chem. 261 1986 14474 14478
61. B. Wiman, B. Ljungberg, J. Chmielewska, G. Urden, M. Blombäck, and H. Johnsson The role of the fibrinolytic system in deep vein thrombosis J. Lab. Clin. Med. 105 1985 265 270
62. J. Wojta, B.R. Binder, K. Huber, and R.L. Hoover Evaluation of fibrinolytic capacity in plasma during thrombolytic therapy with single (scu-PA) or two-chain urokinase type plasminogen activator (tcu-PA) by a combined assay system for urokinase type plasminogen activator antigen and function Thromb. Haemost. 61 1989 289 293
63. D.R. Worthen, O.A. Ghosheh, and P.A. Crooks The in vitro anti-tumor activity of some crude and purified components of blackseed, Nigella sativa L Anticancer Res. 18 3A 1998 1527 1532
64. E. Yesilada, G. Honda, E. Sezik, M. Tabata, T. Fujita, T. Tanaka, Y. Takeda, and Y. Takaishi Traditional medicine in Turkey. V. Folk medicine in the inner Taurus Mountains J. Ethnopharmacol. 46 1995 133 152